Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The Aastrom experience.

Stem cell research & therapy - 9 Jul 2012

Bartel Ronnda L, Cramer Caryn, Ledford Kelly, Longcore Amy, Parrish Christopher, Stern Theresa, Watling Sharon, Zeigler Frank

Abstract excerpt

Aastrom Biosciences has developed a proprietary cell-processing technology that enables the manufacture of ixmyelocel-T, a patient-specific multicellular therapy expanded from a small sample of a patient's own bone marrow. Ixmyelocel-T is produced under current good manufacturing practices (cGMP) in a fully closed, automated system that expands mesenchymal stem cells (MSCs) and macrophages. While the cell types...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antigens, CD
Share to Cardiovascular Diseases
Share to Clinical Trials as Topic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Industry

Share to Kaplan-Meier Estimate

Share to Macrophages

Share to Mesenchymal Stem Cell Transplantation

Share to Mesenchymal Stem Cells

Source

Open in PubMed Open full text

Identifiers

PMID: 22776246
DOI: 10.1186/scrt117
PMCID: PMC3580464

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The Aastrom experience.PMID 22776246Read ↗

Safety of Allogeneic Mesenchymal Stromal Cell Therapy Across Human Clinical Indications: A Systematic Review of Landmark Clinical Trials and Published Safety EvidenceSemantic proximity Read ↗

Regeneration-Associated Cells Improve Recovery from Myocardial Infarction through Enhanced Vasculogenesis, Anti-inflammation, and CardiomyogenesisSemantic proximity Read ↗

Mechanical isolation of stromal vascular fraction using a spiral-based device: cellular outcomes and point-of-care workflow considerationsSemantic proximity Read ↗

Approaches for the isolation and long-term expansion of pericytes from human and animal tissuesSemantic proximity Read ↗

Scalable Generation of Universal hiPSC-Derived Vascular Progenitor Cells for Safe and Sustained Revascularization in Chronic Limb-Threatening IschemiaSemantic proximity Read ↗

Human CardioChimeras: Creation of a Novel ‘Next Generation’ Cardiac CellSemantic proximity Read ↗

Enhancing Myocardial Repair with CardioClustersSemantic proximity Read ↗

Concise Review: The Regenerative Journey of Pericytes Toward Clinical TranslationSemantic proximity Read ↗

Development of a potency assay for CD34+ cell-based therapy for post-acute myocardial infarctionSemantic proximity Read ↗

Phenotyping patient-derived cells for translational studies in cardiovascular disease.Semantic proximity Read ↗

CDC-derived extracellular vesicles reprogram inflammatory macrophages to an arginase 1-dependent proangiogenic phenotype.Semantic proximity Read ↗

Infarct Zone: a Novel Platform for Exosome Trade in Cardiac Tissue RegenerationSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.